Drugs / GGTI-2418
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03900442 | Sep 2019 → Jul 2025 | cancer of unknown primary site | Prescient Therapeutics, Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06854653 | Mar 2025 → Jan 2028 expected | primary cutaneous T-cell lymphoma | Prescient Therapeutics, Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GGTI-2418 | “Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies” NCT03900442 ↗ |
| Known as | PTX-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06854653 ↗ |
| Action | Inhibit | “Geranylgeranyltransferase I Inhibitor PTX-100” NCT03900442 ↗ |
| Modality | Small molecule | — CHEMBL3218390 ↗ |
| Route | Intravenous | “PTX-100 will be administered by IV infusion over 60 minutes” NCT03900442 ↗ |